Table of Contents
Conference Papers in Medicine
Volume 2013 (2013), Article ID 764619, 4 pages
http://dx.doi.org/10.1155/2013/764619
Conference Paper

Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine

Klinik für Innere Medizin-Kardiologie, Schön Klinik Neustadt, Am Kiebitzberg 10, 23730 Neustadt, Germany

Received 24 March 2013; Accepted 14 May 2013

Academic Editors: E. Giannitsis, C. Hamm, M. Möckel, and J. Searle

This Conference Paper is based on a presentation given by Peter W. Radke at “Clinical Decisions in Acute Patients: ACS–POCT–Hypertension and Biomarkers” held from 19 October 2012 to 20 October 2012 in Berlin, Germany.

Copyright © 2013 Peter W. Radke. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. B. Leon, D. S. Baim, J. J. Popma et al., “A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting,” New England Journal of Medicine, vol. 339, no. 23, pp. 1665–1671, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 357, pp. 2001–2015, 2007. View at Google Scholar
  4. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” New England Journal of Medicine, vol. 361, no. 11, pp. 1045–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. W. Hamm, J. P. Bassand, S. Agewall et al., “The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,” European Heart Journal, vol. 32, no. 23, pp. 2999–3054, 2011. View at Publisher · View at Google Scholar
  6. P. G. Steg, S. K. James, D. Atar et al., “The Task Force for the management of acute coronary syndromes (ACS) in patients presenting with persistent ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting with persistent ST-segment elevation,” European Heart Journal, vol. 33, no. 20, pp. 2569–2619, 2012. View at Publisher · View at Google Scholar
  7. S. D. Wiviott, E. Braunwald, D. J. Angiolillo et al., “Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38,” Circulation, vol. 118, no. 16, pp. 1626–1636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. James, A. Budaj, P. Aylward et al., “Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial,” Circulation, vol. 122, no. 11, pp. 1056–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. R. Mehta, C. B. Granger, W. E. Boden et al., “Early versus delayed invasive intervention in acute coronary syndromes,” New England Journal of Medicine, vol. 360, no. 21, pp. 2165–2175, 2009. View at Publisher · View at Google Scholar · View at Scopus